Nano2 dodecafluoropentane emulsion as a cardiac arrest therapeutic

{
  "publication_number": "US2026102360A1",
  "country": "US",
  "kind": "A1",
  "title": "Nano2 dodecafluoropentane emulsion as a cardiac arrest therapeutic",
  "abstract": "The present invention provides methods for treating cardiac arrest in a subject. The methods involve administering to C1 the subject a pharmaceutical composition comprising NANO2 dodecafluoropentane emulsion.",
  "claims": [
    "1. A method of treating a subject with cardiac arrest, comprising administering to the subject a pharmaceutical composition comprising NANO2 dodecafluoropentane emulsion (NuvOx Pharma, LLC, Tucson, Arizona). 2. The method of claim 1, wherein the cardiac arrest is associated with coronary artery disease, valvular heart disease, cardiac dysrhythmias, myocardial infarction, pulmonary disease, arrhythmia, stroke, shock, sepsis, pneumonia, pulmonary embolism, trauma, or COVID-19. 3. The method of claim 1, wherein blood flow has stopped in the subject. 4. The method of claim 1, wherein the pharmaceutical composition is administered intravenously. 5. The method of claim 1, wherein the pharmaceutical composition is injected intravenously via bolus over about 1 to about 10 minutes at a dose of about 0.3 mL/kg of subject body weight to about 1 mL/kg of subject body weight. 6. The method of claim 1, wherein the pharmaceutical composition is injected intravenously via slow IV push over about 1 to about 15 minutes at a dose of about 0.3 mL/kg to about 1 mL/kg of subject body weight. 7. The method of claim 6, wherein the pharmaceutical composition is injected intravenously via slow IV push over about 1 to about 10 minutes. 8. The method of claim 6, wherein the pharmaceutical composition is injected intravenously via slow IV push over about 5 to about 15 minutes. 9. The method of claim 4, wherein the pharmaceutical composition is injected intravenously at a dose of about 0.5 mL/kg of subject body weight. 10. The method of claim 9, wherein the pharmaceutical composition is injected intravenously over about 10 minutes at a dose of about 0.5 mL/kg of subject body weight. 11. The method of claim 1, wherein the pharmaceutical composition is administered as an IV infusion at a rate of about 0.05 mL/kg of subject body weight per hour to about 0.15 mL/kg of subject body weight per hour. 12. The method of claim 1, wherein the pharmaceutical composition is injected intravenously as a sustained IV infusion at a rate of about 0.001 mL/kg of subject body weight per hour to about 0.015 mL/kg of subject body weight per hour. 13. The method of claim 1, wherein the subject is a mammal. 14. The method of claim 13, wherein the mammal is a primate. 15. The method of claim 13, wherein the mammal is a non-human primate. 16. The method of claim 13, wherein the mammal is a human. 17. The method of claim 13, wherein the mammal is a rodent. 18. The method of claim 17, wherein the rodent is a mouse, rat, guinea pig, hamster, or gerbil. 19. The method of claim 13, wherein the mammal is selected from the group consisting of human, baboon, chimpanzee, monkey, cynomolgus, marmoset, rhesus, rodent, rabbit, cat, dog, horse, cow, sheep, goat, pig, ferret, guinea pig, hamster, and gerbil."
  ],
  "cpc": [
    "A61K 31/02",
    "A61K 9/0019",
    "A61K 9/107",
    "A61P 9/04"
  ],
  "filing_date": "2023-10-16",
  "publication_date": "2026-04-16",
  "application_number": "US-202319113821-A"
}